The CDMO ramp is the whole show—commercial projects are stacking up, but the latest print just cooled even as the price already assumes everything lands.
Overall read
4.5/10
Weak & rich
The three reads · this quarter
The CDMO ramp is the whole show—commercial projects are stacking up, but the latest print just cooled even as the price already assumes everything lands.
Overall read
4.5/10
Weak & rich
The three reads · this quarter
The standing reads · change less often
Moat
Moderate edge
Scale and regulatory moat in niche Xanthine; CDMO pipeline promising but unproven long-term.
Key variables
4 tracked
lead: CDMO pipeline: commercial vs development projects & customersCommercial projects have compounded (13->37) while development stays flat and customers barely widen (12->22), so CDMO is deepening existing relationships into recurring commercial supply rather than winning many new logos - the flat development count is the watch-item since today's development projects are tomorrow's commercial revenue.
Walk the talk
Xanthine capacity expansion to 9,600 MTPA with ramp-up to 80%+ by FY28.
Weak
1 of 5 guidance items delivered on time
Where it sits